Corel Medical Series: Cancer/Corel Medical Series: Cancer.iso/mac/Program/Indexdat/indexc.A

Text File | 1997-01-27 | 6KB | 2 lines

Abdominal-perineal resection,c02.15;c08.10,Abortion risk factor,c43.4,Acetaminophen,p19.8;c04.4,Achlorhydria,c39.3,Acromegaly,c34.1,ACTH-producing tumor,c34.1;c34.5;c34.6,Actinomycin-D,7,Active-specific immunotherapy,c25.17,Active stimulation immunotherapy,p08.5,Activity,p16.20;p16.21;p16.22;p17.5;p17.6;p17.7;,Acupressure,p25.7,Acupuncture,p13.16,Acute leukemia,11,Acyclovir,p17.18;p20.7,Addiction,p19.11,Addison's disease,c41.2,Adenoacanthoma,c44.1,Adenocarcinoma,20,Adenoma,4,Adenosquamous carcinoma,3,Adjunctive therapies unproven,p13.8,Adjuvant therapy,3,Adoptive immunotherapy,p08.6,Adrenal gland cancer,12,Adrenal insufficiency,c41.2,Adrenergic blockers,c08.9,Adrenocortical carcinoma,c01.2;c01.9;c01.12,Advance Directive,p32.4,Affirmation,p29.9,Age,13,AIDS,6,AlDS-related cancers,p01.8,Albinism,c37.5,Alcohol,3,Aldosteronoma,c01.1,Alkaloids,p07.6,Alkylating agents,p07.6;p11.5;c04.6;c28.12,All trans retinoic acid,p35.13,All-trans retinoic acid,c18.15,Allergic reaction to biological therapy,p08.18,Allogeneic bone marrow transplantation,p12.5,Allopurinol,c18.25,Alternative medicine,p13.15,American Cancer Society (ACS)  Seven Early Warning Signals,p02.3,Amifostine,p35.15,Amine precursor uptake and decarboxylation (APUD) tumor,c08.2;c21.2,Amphogel,p06.19,Amphotericin B,p20.7,Amsacrine,c18.18,Anagrelide,c18.26,Anal canal cancer,c02.3,Anal cancer,12,Anal margin cancer,c02.2,Analgesics,2,Anaphylaxis from biological therapy,p08.18,Anaplastic carcinoma thyroid,c42.23,Anaplastic seminoma testis cancer,c40.1,Androstenedrione,p23.19,Anemia,p02.7;c39.4;c39.7;c41.2,Anesthesia,2,Anesthesiologist role,p05.14,Aneuploid tumor,c11b.8,Anger,p03.15;p16.9,Angiography,p02.13,Angiosarcoma,2,Anorexia,p17.20,Antacids,p17.23,Anthrapyrazoles,c06.53,Antiandrogens,c35.18;c35.29,Antibiotics,3,Antibodies,12,Anticipatory nausea and vomiting,p17.13,Anticonvulsants,p19.8,Antidepressants,p17.23;p19.8;p23.8,Antiemetics,p17.14,Antifolate compounds,p35.8,Antifungal drugs,p20.7,Antigens,3,Antihypertensive drugs,p23.8,Antimetabolites,p07.6;p35.9;p35.10,Antinausea drugs,p17.14,Antispasmodics,p17.23,Antitumor antibiotics,p07.6,Antiviral drugs,p19.5;p20.7,Apheresis,p14.8,Appendectomy,c08.10,Appendiceal carcinoid,c08.10,Appetite loss of,p17.20;p18.3,Ara-C for ovarian cancer,c29.20,Armpit lymph nodes cancer of unknown primary site,c07.14,Asbestos,p01.7;p34.7;c26.2;c26.3,L-Asparaginase,c18.19,Aspirin,p19.8;p27.6,Assistive Devices Program (provincial),p21.13;p26.5,Association canadienne des infirmiËres en oncologie (ACIO),p15.3,Astrocytoma,7,Ataxia telangiectasia,c10a.5,Atomic Energy Control Board,p03.8,Atypical hyperplasia,c06.5;c06.8,Autologous blood transfusion,p14.10,Autologous bone marrow transplantation,p08.15;p12.6,Autologous peripheral stem cell transplant,p12.7,Azacitidine,p35.12,5-Azacytidine,c26.11,AZT,c16.16;c16.19,
for Ewing's sarcoma,c10d.11,for ovarian cancer,c30.13;c30.16,for rhabdomyosarcoma,c10d.4;c10d.6,for testis cancer,chr.c40.17,for trophoblastic disease,c43.14;c43.15,for uterine cancer,c45.11;c45.12;c45.14;c45.17,for vaginal cancer,c46.13,defined,c18.2,lymphoblastic,c10a.1;c10a.14;c10a.16;c18.19,lymphocytic,c10a.5;c18.1,monoblastic,c18.15,monocytic,c18.15,myeloblastic,c18.18,myelogenous,c18.,myeloid,c18.15,non-lymphoblastic,c10a.1;c10a.16,promyelocytic,c18.15,treatment,c18.13,anus,c02.2,bile duct,c03.1,bladder,c04.3;c04.25,breast,c06.3,cervix,c09.1;c09.7;c09.12,colorectal,c11a.2,endometrium,c44.1,esophagus,c12.2,gall bladder,c13.1,intraductal,c35.32,kidney,c17.2,liver,c19.1;c19.17,lung,c20.2,pancreas,c31.1,prostate,c35.2,small intestine,c38.2;c38.11,stomach,c39.2,unknown primary site,c07.3,vagina,c46.1;c46.9;c46.10;c46.11,vulva,c47.2;c47.18,adrenocortical,c01.2,chromophobe,c34.1;c34.7,cortical,c01.2,pituitary,c05.20,cervix,c09.2;c09.7,endometrium,c44.2,pancreas,c31.1,after surgery,p07.3,chemotherapy,p04.7;p07.15,immunotherapy,p08.5,child,c01.2,diagnosis,c01.9,follow-up,c01.17,questions to ask,c01.19,recurrence,c01.18,risk factors,c01.4,screening,c01.5,spread,c01.3,staging,c01.11,symptoms,c01.7,treatment,c01.12,types,c01.1,breast cancer,c06.5;c06.6,colorectal cancer,c11a.4,Kaposi's sarcoma,c16.4,multiple myeloma,c28.5,pancreatic cancer,c31.3,penile cancer,c33.3,prostate cancer,c35.5,small intestine cancer,c38.4,stomach cancer,c39.4,testis cancer,c40.6,treatment options,p04.12,trophoblastic disease,c43.5,uterine sarcoma,c45.4,anal cancer,c02.3,blood transfusion,p14.3;p14.13,brain tumor,c05.2,CNS lymphoma,c05.20,Kaposi's sarcoma,c16.1;c16.3;c16.4;c16.5;c16.6;c16.8;c16.13;c16.14;c16.16,lymphoma,c22.1,mouth irritant,p17.19,risk factor,p01.8;p34.12;c12.3;c12.4;c14a.5;c31.3,and sexual dysfunction,p23.8,causes,c02.2,diagnosis,c02.6,follow-up,c02.16,questions to ask,c02.18,recurrence,c02.17,risk factors,c02.3,screening,c02.4,spread,c02.2,staging,c02.8,symptoms,c02.5,treatment,p09.8;c02.9,types,c02.1,defined,p27.6,post-operative pain,p05.17;p05.18,risks,p05.17,types,p05.13,liver,c19.1;c19.17;chr.c36.2.,small intestine,c38.2,antitumor,p07.6,causing diarrhea,p17.28,to fight infection,p20.9,immune response,p08.3,monoclonal (MAbs) about,p08.13,for breast cancer,c06.47;c06.53,for colorectal cancer,c11b.21;c11b.25;c11c.15,for kidney cancer,c17.11,for leukemia,c18.20;c18.23,for liver cancer,c19.13,for melanoma,c25.18,for ovarian cancer,c29.20,investigational,p35.17,parts,p08.13,side effects,p08.17,and bone marrow transplantation,p12.6,defined,p08.3,in donated blood,p14.4;p14.5;p14.6,anaplastic,c10b.15,cerebellar,c10b.11,cerebral,c10b.14;c10b.15,child,c10b.2;c10b.14;c10b.15,defined,c05.1,spinal cord,c05.23,treatment,c05.17,